Potential Adverse Effects of HER2-Targeted Therapies

  • Trastuzumab and pertuzumab can cause:
    • Decrease in ejection fraction in up to 20% of patients:
      • Although this is often reversible
  • Trastuzumab:
    • Can less commonly cause pneumonitis
  • Pertuzumab:
    • Can cause rash and diarrhea
  • References:
    • Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
    • Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278-2284.

#Arrangoiz #CancerSurgeon #BreastSurgeon #CASO #CenterforAdvancedSurgicalOncology #BreastCancer

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s